Characterization of Patients With Advanced Pancreatic Cancer and High Serum Interleukin-6 Levels

被引：76

作者：

Miura, Tomofumi ^{[1
,2
,3
]}

Mitsunaga, Shuichi ^{[1
,3
]}

Ikeda, Masafumi ^{[1
]}

Shimizu, Satoshi ^{[1
]}

Ohno, Izumi ^{[1
]}

Takahashi, Hideaki ^{[1
]}

Furuse, Junji ^{[4
]}

Inagaki, Masatoshi ^{[5
]}

Higashi, Sayumi ^{[6
]}

Kato, Hiroyuki ^{[6
]}

Terao, Kimio ^{[6
]}

Ochiai, Atsushi ^{[3
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba 2778577, Japan

[2] Natl Canc Ctr Hosp East, Dept Palliat Med, Kashiwa, Chiba 2778577, Japan

[3] Natl Canc Ctr Hosp East, Div Pathol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan

[4] Kyorin Univ, Sch Med, Dept Med Oncol, Mitaka, Tokyo 181, Japan

[5] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Ctr Suicide Prevent, Kodaira, Tokyo, Japan

[6] Chugai Pharmaceut Co Ltd, Tokyo, Japan

来源：

PANCREAS | 2015年 / 44卷 / 05期

关键词：

pancreatic cancer; interleukin; 6; anti-IL-6; therapy; cancer cachexia; INFLAMMATORY CYTOKINES; COLORECTAL-CANCER; PROTEIN-SYNTHESIS; HEPCIDIN; FATIGUE; TUMOR; CARCINOMA; IL-6; ADENOCARCINOMA; PROGRESSION;

D O I：

10.1097/MPA.0000000000000335

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Objectives High serum level of interleukin 6 (IL-6) is associated with high degree of tumor progression and systemic weakness. Anti-IL-6 therapy possibly improves the deterioration of clinical characteristics in patients with high IL-6 level. However, IL-6-related factors in patients with treatment-naive advanced pancreatic cancer (PC) have not been established. The goal of this study was to identify IL-6-related factors in patients with advanced PC who were scheduled to undergo first-line chemotherapy. Methods Patients with treatment-naive advanced PC were eligible for inclusion in this study. Patients who did not receive first-line chemotherapy were excluded. Serum IL-6 levels and clinical parameters were prospectively recorded. Analyses were performed to identify risk factors for high IL-6 levels. Results Eighty patients were analyzed. IL-6-related factors were advanced age (P < 0.01), the presence of liver metastasis (P < 0.01), the large volume of liver metastasis (P < 0.01), severe fatigue (P = 0.02), high carcinoembryonic antigen levels (P = 0.02), anemia (P < 0.01), and high C-reactive protein levels (P = 0.02) in multivariate analyses. Decreased skeletal muscle mass tended to be associated with high IL-6 levels. Conclusions High serum IL-6 was related to advanced age, the presence of hepatic metastasis, large tumor burden in liver, severe fatigue, high carcinoembryonic antigen, high C-reactive protein, and anemia in patients with treatment-naive advanced PC.

引用

页码：756 / 763

页数：8

共 38 条

[1] Activation state of stromal inflammatory cells in murine metastatic pancreatic adenocarcinoma [J].

Benson, Douglas D. ;

Meng, Xianzhong ;

Fullerton, David A. ;

Moore, Ernest E. ;

Lee, Joon H. ;

Ao, Lihua ;

Silliman, Christopher C. ;

Barnett, Carlton C., Jr. .

AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2012, 302 (09) :R1067-R1075

[2] Symptoms in advanced pancreatic cancer are of importance for energy intake [J].

Bye, Asta ;

Jordhoy, Marit S. ;

Skjegstad, Grete ;

Ledsaak, Oddlaug ;

Iversen, Per Ole ;

Hjermstad, Marianne Jensen .

SUPPORTIVE CARE IN CANCER, 2013, 21 (01) :219-227

[3] ACUTE-PHASE RESPONSE OF HUMAN HEPATOCYTES - REGULATION OF ACUTE-PHASE PROTEIN-SYNTHESIS BY INTERLEUKIN-6 [J].

CASTELL, JV ;

GOMEZLECHON, MJ ;

DAVID, M ;

FABRA, R ;

TRULLENQUE, R ;

HEINRICH, PC .

HEPATOLOGY, 1990, 12 (05) :1179-1186

[4] INTERLEUKIN-6 INDUCES PROTEOLYSIS BY ACTIVATING INTRACELLULAR PROTEASES (CATHEPSIN-B AND CATHEPSIN-L, PROTEASOME) IN C2C12 MYOTUBES [J].

EBISUI, C ;

TSUJINAKA, T ;

MORIMOTO, T ;

KAN, K ;

IIJIMA, S ;

YANO, M ;

KOMINAMI, E ;

TANAKA, K ;

MONDEN, M .

CLINICAL SCIENCE, 1995, 89 (04) :431-439

[5] Cytokines in pancreatic carcinoma - Correlation with phenotypic characteristics and prognosis [J].

Ebrahimi, B ;

Tucker, SL ;

Li, DH ;

Abbruzzese, JL ;

Kurzrock, R .

CANCER, 2004, 101 (12) :2727-2736

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] Hepcidin and Disorders of Iron Metabolism [J].

Ganz, Tomas ;

Nemeth, Elizabeta .

ANNUAL REVIEW OF MEDICINE, VOL 62, 2011, 2011, 62 :347-360

[8] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[9] Signs and Symptoms of Pancreatic Cancer: A Population-Based Case-Control Study in the San Francisco Bay Area [J].

Holly, Elizabeth A. ;

Chaliha, Indranushi ;

Bracci, Paige M. ;

Gautam, Manjushree .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (06) :510-517

[10] Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli [J].

Huang, Hua ;

Constante, Marco ;

Layoun, Antonio ;

Santos, Manuela M. .

BLOOD, 2009, 113 (15) :3593-3599

← 1 2 3 4 →